India’s government reaffirmed its ban on e‑cigarettes and heated‑tobacco devices on February 11 2026, a decision that echoes the original prohibition enacted in September 2019. The reaffirmation was announced as a policy statement, not a new regulatory change, but it constitutes a fresh disclosure that affects the market outlook for companies seeking entry.
The ban removes a key growth avenue for Philip Morris International (PMI), which had been lobbying the Indian government for years to secure an exemption. PMI’s strategy has centered on expanding its smoke‑free portfolio—IQOS and Swedish Match’s ZYN nicotine pouches—into high‑volume markets. India’s market, with over 100 billion cigarettes sold annually, represents a significant untapped opportunity; the ban therefore limits PMI’s ability to diversify revenue and pursue its “smoke‑free future” narrative.
PMI’s global strategy has been underpinned by regulatory approvals in other jurisdictions. IQOS received U.S. FDA approval in 2019 and was granted modified‑risk status in 2020, while ZYN was approved in January 2025. The Indian ban curtails the company’s ability to leverage these approvals in a large, price‑sensitive market, constraining its growth trajectory in the region.
In its most recent earnings, PMI reported Q4 2025 adjusted earnings per share of $1.70, beating consensus estimates by $0.05. The beat was driven by strong demand for IQOS in the United States and Europe, coupled with disciplined cost management. Management maintained a positive outlook for 2026, projecting adjusted EPS of $8.38‑$8.53, a range that reflects confidence in continued growth in other markets despite the Indian setback.
The reaffirmation was a strategic setback for PMI’s smoke‑free expansion, but analysts noted that the company’s other markets—particularly the U.S., Europe, and emerging economies—continue to grow robustly. PMI’s CEO described the Indian ban as “illogical” and reiterated the company’s commitment to engaging regulators worldwide to advance smoke‑free alternatives.
India’s public‑health rationale centers on preventing a new generation of nicotine addiction, especially among youth. The ban reflects a broader global trend of stricter regulation of heated‑tobacco products, underscoring the challenges PMI faces in aligning its product portfolio with diverse regulatory environments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.